Recent failures in Big Pharma drug development, where billions were invested in AI-recommended heart drugs, highlight the limitations of current AI large language models. Despite impressive speed and human-like responses, these models lack true reasoning capabilities and are essentially sophisticated computer programs. The halted Phase 3 trials for drugs from Novartis and Novo Nordisk, which showed no benefit over placebos, serve as a cautionary tale against overhyping AI's potential to rapidly cure diseases. AI
IMPACT Highlights the current limitations of AI in complex reasoning tasks, tempering expectations for rapid disease cures driven solely by AI.
RANK_REASON The article discusses the implications of failed AI-driven drug trials, offering an opinion on AI hype rather than reporting a new release or research breakthrough.
Read on Mastodon — sigmoid.social →
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →